{
  "id": "mhgap#screening_cues_8e310d3b",
  "content": "low certainty); modafinil (low certainty); prescription\n67\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nRemarks y There are no studies in non-specialized settings.\ny There is insufficient evidence to support use of Further research in these settings would be\nnaltrexone, dexamphetamine, methylphenidate, beneficial in understanding feasibility, acceptability\nmodafinil, topiramate, mirtazapine or bupropion and effectiveness.\nfor the treatment of stimulant use disorders in y Most of the evidence is of low or very low quality\nnon-specialized settings. with high levels of uncertainty. This is very much\ny The term “cocaine or stimulant use disorders” refers attributable to the high dropout rates observed in\nto diagnosis according to the ICD-10, DSM-IV criteria most of the trials, and lack of data on techniques to\nor equivalent ICD-11 and DSM-5 diagnosis. reduce attrition.\ny Pharmacological treatment considered in\nImplementation considerations\nthe current review included: naltrexone,\ny Some medicines have potential for abuse and\ndexamphetamine, methylphenidate, modafinil,\nadverse effects (such as prescription amphetamines/\ntopiramate, mirtazapine and bupropion.\ndexamphetamine and methylphenidate).\ny Most of the trials using above medicines had\ny Service providers should assess psychosocial\nelevated dropout rates which severely impacted\nstressors (e.g. domestic abuse, unemployment)\ntheir results.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "stress",
      "study",
      "screening_cues",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues low certainty); modafinil (low certainty); prescription\n67\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nRemarks y There are no studies in non-specialized settings.\ny There is insufficient evidence to support use of Further research in these settings would be\nnaltrexone, dexamphetamine, methylphenidate, beneficial in understanding feasibility, acceptability\nmodafinil, topiramate, mirtazapine or bupropion and effectiveness.\nfor the treatment of stimulant use disorders in y Most of the evidence is of low or very low quality\nnon-specialized settings. with high levels of uncertainty. This is very much\ny The term “cocaine or stimulant use disorders” refers attributable to the high dropout rates observed in\nto diagnosis according to the ICD-10, DSM-IV criteria most of the trials, and lack of data on techniques to\nor equivalent ICD-11 and DSM-5 diagnosis. reduce attrition.\ny Pharmacological treatment considered in\nImplementation considerations\nthe current review included: naltrexone,\ny Some medicines have potential for abuse and\ndexamphetamine, methylphenidate, modafinil,\nadverse effects (such as prescription amphetamines/\ntopiramate, mirtazapine and bupropion.\ndexamphetamine and methylphenidate).\ny Most of the trials using above medicines had\ny Service providers should assess psychosocial\nelevated dropout rates which severely impacted\nstressors (e.g. domestic abuse, unemployment)\ntheir results. Low certainty); modafinil (low certainty); prescription\n67\nmental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders\nremarks y there are no studies in non-specialized setti..."
}